Short-term HbA1c non-inferiority should not be interpreted as proof of complete therapeutic interchangeability, particularly regarding cardiovascular outcomes, renal protection, long-term safety, or substitution across all clinical settings
Here is a practical framework for navigating these conversations
Counsel outlined the procedural posture of those cases, any upcoming trial settings or dispositive motions, and coordination issues between the MDL and parallel state proceedings
The research, published in the journal JAMA Psychiatry, was funded by the US National Institutes of Health (NIH)
Medicare Part D plans generally do not cover medications prescribed solely for weight loss, as federal law (Social Security Act 1860D-2(e)(2)(A)) explicitly excludes weight loss drugs from Medicare coverage